Information Provided By:
Fly News Breaks for December 18, 2019
Dec 18, 2019 | 10:28 EDT
JMP Securities analyst Jason Butler reiterates an Outperform rating on Pfenex (PFNX) with a $19 price target after the company earned a process-development milestone from Jazz Pharmaceuticals (JAZZ) for the long-acting form of asparaginase, PF745. Pfenex also noted that Jazz remains on track to recruit patients for the pivotal Phase 2/3 trial of PF743 as early as by the end of 2019, Butler tells investors in a research note. The analyst believes that the Jazz partnered programs will continue to increase in importance for Pfenex shares.
News For PFNX;JAZZ From the Last 2 Days
There are no results for your query PFNX;JAZZ